IN FOCUS FEATURE
Wake Forest Offers Bioethics MA; First in NC and Surrounding States
FROM OUR WEB SITE
Wake Forest Offers Bioethics MA; First in NC and Surrounding States
A new master's program in bioethics will soon commence at Wake Forest University. The program will equip graduates to practice, teach or conduct research about bioethics.
Currently, there are no comparable programs in North Carolina or in surrounding states. The university is already accepting applications and classes will begin in fall 2009.
Read more about the Wake Forest curriculum in this week's In Focus.
From Our Web Site
CED Forum on Clinical Trials
CED's Biotech Forum Clinical Trials - Adaptive Trial Design & Best Practices in Clinical Development Strategies.
Zen-Bio Gets SBIR for $200K
RTP-based Zen-Bio landed a $200K Phase I SBIR grant to improve breast cancer analysis.
WFU No. 2 in Tech Transfer
Wake Forest University’s technology transfer team is the nation’s second-best at spinning university scientists’ inventions into gold.
8 NC Firms in SE BIO Forum
Eight of the 29 young bioscience firms in this year's SE BIO Investor Forum are from North Carolina – all headquartered in the Research Triangle area.
BioMerieux Buys California Firm
BioMerieux, a French medical diagnostics company with U.S. headquarters in Durham, is paying $60 million to buy a California concern.
Talecris Drug Gets FDA OK
Research Triangle Park-based Talecris Biotherapeutics' has received regulatory approval for its medicine, Gamunex, as the first treatment for chronic inflammatory demyelinating polyneuropathy, or CIDP.
Utah Nanotech Relocates to NC
QualSec, developer of the Nanonose, cites quality workforce as the reason for its move.
Inspire to Start Glaucoma Trial
Durham-based Inspire Pharmaceuticals plans to start Phse I trials of its glaucoma treatment. The FDA's standard 30-day review period for its investigational new drug application has concluded.
250 Attend Seminar to Learn About MURDOCK Study
Duke University's MURDOCK study researches why some people get sick and others don't, and why some patients respond to drug treatments and others only suffer side effects with no benefit.
From the Salisbury Post
From Local Tech Wire
-
Research Triangle Park-based Tryton Medical, a developer of novel stent systems for the treatment of cardiovascular disease, has appointed Brett Farabaugh, the former chief financial officer of the data delivery firm StrikeIron, as Tryton’s chief financial officer. Douglas Ferguson has also joined Tryton as its regulatory and clinical vice president.
-
Brian Moynihan, founder of Agile Web Enterprises, has joined Chapel Hill-based QualSec as director of operations. QualSec, developer of the NanoNose electronic nose technology, is relocating its operations from North Logan, Utah to Chapel Hill. NanoNose is designed to analyze and quantify airborne particles for the homeland security, health care, environmental, petrochemical and food industries.
-
Ron Kershner, Ph.D., vice president of biostatistics and data management at Wilmington-based AAIPharma, will present “The Role of the Data Monitoring Committee” at the Society of Clinical Research Associates Annual Conference in Vancouver, BC., next Friday. The presentation will be available on the AAIPharma Web site, at www.aaipharma.com/mediacenter starting September 29.
Please send Community Watch items to Jim Shamp.
October 22
NC Marine Biotech Forum
(Wilmington)
October 28
Charlotte Biotechnology Conference
(Charlotte)
December 4-5
SE BIO Investor Forum
(Palm Beach, Fla.)
February 16-17
Biotech 2009
(Raleigh)
May 18-21
BIO International Convention
(Atlanta)
View our complete listing of events across North Carolina.
This newsletter was sent Thursday, September 18, 2008. For the latest headlines from North Carolina's biotechnology industry, please visit the news section of our Web site.
Online subscription management is now available. Please respond to this e-mail if you cannot change your preferences online.